Jacobio Pharmaceuticals Group (JBPHF) Stock Price, News & Analysis

Company Overview

Jacobio Pharmaceuticals Group Co., Ltd. is a China-based clinical-stage biopharmaceutical company focused on discovering and developing innovative medicines for cancer and other serious diseases. The company’s research programs are primarily centered on small-molecule therapies designed to target cancer-driving proteins and signaling pathways.

Jacobio’s pipeline includes glecirasib, also known as JAB-21822, an investigational KRAS G12C inhibitor being developed for cancers involving KRAS G12C mutations. The company is also advancing other oncology candidates, including JAB-3312, a SHP2 inhibitor, and additional programs aimed at targets associated with tumor growth, treatment resistance and immune regulation.

Founded in 2015, Jacobio conducts research and clinical-development activities in China and has pursued international development and collaboration opportunities for selected programs. The company is listed on the Hong Kong Stock Exchange under the symbol 1167, while its American depositary security trades over the counter in the United States under the symbol JBPHF.

Key Stats

• Today's Range: $0.76 to $0.76
• 50-Day Range: $0.68 to $0.76
• 52-Week Range: $0.60 to $0.76
• Volume: N/A
• Average Volume: 1,180 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:JBPHF
• CIK: N/A
• Web: www.jacobiopharma.com
• Phone: 86-10-5631-5466
• Fax: N/A
• Employees: 301
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A